Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Sep 30, 2019
Jun 30, 2019
Mar 31, 2019
Dec 31, 2018
Total Revenue
461,097
--
400,745
353,214
Cost of Revenue
96,949
--
89,182
75,019
Gross Profit
364,148
--
311,563
278,195
Operating Expenses
Research Development
172,963
--
183,591
175,390
Selling General and Administrative
170,112
--
162,158
164,171
Non Recurring
--
--
--
--
Others
17,063
--
19,765
6,782
Total Operating Expenses
360,138
--
365,514
346,343
Operating Income or Loss
4,010
--
(53,951)
(68,148)
Income from Continuing Operations
Total Other Income/Expenses Net
3,409
--
1,423
26,893
Earnings Before Interest And Taxes
12,759
--
(46,230)
(36,157)
Interest Expense
2,937
--
6,727
7,154
Income Before Tax
9,822
--
(52,957)
(43,311)
Income Tax Expense
(45,214)
--
3,516
(39,661)
Minority Interest
--
--
--
--
Net Income From Continuing Ops
55,036
--
(56,473)
(3,650)
Non-recurring Events
Discontinued Operations
--
--
--
--
Extraordinary Items
--
--
--
--
Effect Of Accounting Changes
--
--
--
--
Other Items
0
--
0
0
Net Income
55,036
--
(56,473)
(3,650)
Preferred Stock And Other Adjustments
--
--
--
--
Net Income Applicable To Common Shares
55,036
--
(56,473)
(3,650)

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq®
Brineura®
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information